Bausch Health Companies Inc. (TSE:BHC) to Post Q3 2022 Earnings of $1.34 Per Share, Zacks Research Forecasts

Bausch Health Companies Inc. (TSE:BHCGet Rating) – Analysts at Zacks Research lifted their Q3 2022 EPS estimates for shares of Bausch Health Companies in a report released on Tuesday, September 20th. Zacks Research analyst E. Bagri now expects that the company will post earnings per share of $1.34 for the quarter, up from their prior estimate of $1.33. The consensus estimate for Bausch Health Companies’ current full-year earnings is $6.17 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q4 2022 earnings at $1.23 EPS, FY2022 earnings at $4.27 EPS, Q1 2023 earnings at $1.37 EPS, Q2 2023 earnings at $1.30 EPS, Q3 2023 earnings at $1.32 EPS, Q4 2023 earnings at $1.08 EPS, Q2 2024 earnings at $1.54 EPS and FY2024 earnings at $6.20 EPS.

Separately, Guggenheim increased their target price on shares of Bausch Health Companies from C$24.00 to C$26.00 in a research report on Monday, August 8th.

Bausch Health Companies Price Performance

Shares of BHC opened at C$9.63 on Thursday. The company has a current ratio of 1.08, a quick ratio of 0.46 and a debt-to-equity ratio of 8,622.13. The firm’s fifty day simple moving average is C$8.54 and its 200-day simple moving average is C$15.61. The firm has a market capitalization of C$3.48 billion and a price-to-earnings ratio of 50.68. Bausch Health Companies has a twelve month low of C$5.10 and a twelve month high of C$37.42.

Bausch Health Companies (TSE:BHCGet Rating) last announced its quarterly earnings data on Tuesday, August 9th. The company reported C$0.71 earnings per share for the quarter, missing analysts’ consensus estimates of C$1.15 by C($0.44). The firm had revenue of C$2.51 billion for the quarter, compared to analyst estimates of C$2.63 billion.

Insider Activity at Bausch Health Companies

In other Bausch Health Companies news, Director Joseph Papa sold 100,000 shares of the firm’s stock in a transaction on Wednesday, September 14th. The shares were sold at an average price of C$9.84, for a total transaction of C$983,534.70. Following the transaction, the director now directly owns 934,594 shares of the company’s stock, valued at approximately C$9,192,056.29.

Bausch Health Companies Company Profile

(Get Rating)

Bausch Health Companies Inc, together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products.

Read More

Earnings History and Estimates for Bausch Health Companies (TSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with's FREE daily email newsletter.